Aquestive Therapeutics Reports Q2 2026 Results

What Happened

• Aquestive Therapeutics, Inc. issued a press release on August 11, 2026 announcing its reported financial results for the second quarter ended June 30, 2026 and providing an update on recent business developments. The press release and accompanying financial schedules are attached to the Form 8-K as Exhibit 99.1.
• The company also furnished an investor presentation for meetings with institutional investors and analysts (Regulation FD disclosure); that presentation is attached as Exhibit 99.2 and may be updated over time. The Form 8-K was signed by CFO A. Ernest Toth, Jr.

Key Details

• Filing date: August 11, 2026 (Form 8-K).
• Reported period: Second quarter ended June 30, 2026.
• Exhibits included: Exhibit 99.1 (press release with financial schedules) and Exhibit 99.2 (Q2 earnings supplemental materials / investor presentation).
• Reg FD disclosure: presentation provided to investors/analysts and may be amended in future filings.

Why It Matters

• This 8‑K is the company’s official disclosure of its Q2 2026 quarterly results and business update; investors should review Exhibit 99.1 and 99.2 for revenue, earnings, cash flow, and any management commentary or guidance.
• The investor presentation (Reg FD) helps ensure material information shared with analysts and institutions is publicly available; changes in quarterly results or strategic updates can influence the stock and investor decisions.
• Because the Form 8‑K references the press release and slides for details, retail investors should read those exhibits for the specific financial figures and management commentary.